# Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

> **NCT04446234** · PHASE4 · UNKNOWN · sponsor: **Shanghai Mental Health Center** · enrollment: 350 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Aripiprazole
- **DRUG:** Ziprasidone
- **DRUG:** Amisulpride
- **DRUG:** Quetiapine

## Key facts

- **NCT ID:** NCT04446234
- **Lead sponsor:** Shanghai Mental Health Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2020-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446234, "Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04446234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*